Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N
Department of Emergency and Organ Transplantation-Section on Internal Medicine, Endocrinology and Metabolic Diseases, University of Bari School of Medicine, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Diabetologia. 2004 Jun;47(6):1020-8. doi: 10.1007/s00125-004-1413-8. Epub 2004 May 29.
AIMS/HYPOTHESIS: Type 1 diabetic patients who develop microalbuminuria are clearly disadvantaged in terms of their risk of morbidity and mortality from renal and cardiovascular diseases. It is therefore important to identify potential factors that can predict progression to macroalbuminuria.
This is a 7-year follow-up study of 352 microalbuminuric Type 1 diabetic patients from 31 European centres. Risk factors at baseline were compared in patients who progressed to macroalbuminuria and in patients who remained microalbuminuric or reverted to normoalbuminuria. Risk factors and albumin excretion rate (AER) were measured centrally.
Over 7.3 years, 13.9% of the microalbuminuric patients progressed to macroalbuminuria, 35.5% remained microalbuminuric and 50.6% reverted to normoalbuminuria. Independent baseline risk factors for progression to macroalbuminuria were HbA(1)c (7.9% vs 6.8%, p=0.004), AER (64.4 vs 44.9 microg/min, p=0.0001) and-after adjusting for diabetes duration, HbA(1)c and AER-body weight (72 vs 67 kg, p=0.05). Independent factors associated with regression to normoalbuminuria were diabetes duration (15 vs 18 years, p=0.004), AER (37.2 vs 44.9 microg/min, p=0.0001) and-after adjusting for diabetes duration, HbA(1)c and AER-waist-to-hip ratio (0.83 vs 0.86, p=0.05) and incidence of peripheral neuropathy at baseline (24% vs 38%, p=0.001). Blood pressure and smoking did not emerge as risk factors at baseline for the outcome of microalbuminuria.
CONCLUSIONS/INTERPRETATION: A significant fraction of microalbuminuric Type 1 diabetic patients will progress to overt proteinuria. Patients with higher AER values, sub-optimal metabolic control, excess body fat and peripheral neuropathy may carry a particularly high risk of clinical nephropathy requiring aggressive therapeutic intervention.
目的/假设:出现微量白蛋白尿的1型糖尿病患者在罹患肾脏疾病和心血管疾病导致的发病及死亡风险方面明显处于劣势。因此,识别能够预测进展为大量白蛋白尿的潜在因素很重要。
这是一项对来自31个欧洲中心的352例微量白蛋白尿1型糖尿病患者进行的为期7年的随访研究。对进展为大量白蛋白尿的患者以及仍为微量白蛋白尿或恢复为正常白蛋白尿的患者的基线风险因素进行了比较。风险因素和白蛋白排泄率(AER)在中心实验室进行测量。
在7.3年的时间里,13.9%的微量白蛋白尿患者进展为大量白蛋白尿,35.5%仍为微量白蛋白尿,50.6%恢复为正常白蛋白尿。进展为大量白蛋白尿的独立基线风险因素为糖化血红蛋白(HbA1c)(7.9%对6.8%,p = 0.004)、AER(64.4对44.9微克/分钟,p = 0.0001),以及在调整糖尿病病程、HbA1c和AER后,体重(72对67千克,p = 0.05)。与恢复为正常白蛋白尿相关的独立因素为糖尿病病程(15对18年,p = 0.004)、AER(37.2对44.9微克/分钟,p = 0.0001),以及在调整糖尿病病程、HbA1c和AER后,腰臀比(0.83对0.86,p = 0.05)和基线时周围神经病变的发生率(24%对38%,p = 0.001)。血压和吸烟在基线时未表现为微量白蛋白尿结局的风险因素。
结论/解读:相当一部分微量白蛋白尿的1型糖尿病患者会进展为显性蛋白尿。AER值较高、代谢控制欠佳、体脂过多和周围神经病变的患者可能面临临床肾病的特别高风险,需要积极的治疗干预。